Prescription Drug Spending Remains Low, As Generics Continue To Dominate -Medco
This article was originally published in The Pink Sheet Daily
OTC entries drive Rx utilization down.
You may also be interested in...
Long-term cancer treatment with targeted oral therapies will spur a 46 percent to 53 percent surge in health plan spending on oncology drugs within the next three years, Medco predicts in its 2008 Drug Trend Report (see chart: "1Drug Spending By Health Plans: 2008-2010 Forecast")
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.